INDP Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
1.8M
-16.2%
2.2M
-73.5%
8.2M
+207.9%
2.6M
-40.6%
4.5M
R&D
363.1K
-26.1%
491.1K
-82.7%
2.8M
+87.5%
1.5M
-30.0%
2.2M
SG&A
1.4M
-13.3%
1.7M
-68.6%
5.3M
+369.6%
1.1M
-50.6%
2.3M
Operating Income
-1808866
+16.2%
-2159588
+73.5%
-8155704
-207.9%
-2648487
+40.6%
-4456763
EBITDA
-1808866
+16.2%
-2159588
+73.5%
-8155704
-207.9%
-2648487
+40.6%
-4456763
Net Income
-1794863
+29.4%
-2541070
+68.7%
-8112450
-172.7%
-2975117
+43.1%
-5228919
EPS (Basic)
$-0.02
+91.3%
$-0.23
+94.9%
$-4.52
-51.7%
$-2.98
+67.2%
$-9.09
EPS (Diluted)
$-0.02
+91.3%
$-0.23
+94.9%
$-4.52
-51.7%
$-2.98
+67.2%
$-9.09
Shares (Diluted)
116.1M
+959.9%
11.0M
+510.5%
1.8M
+80.0%
997.0K
+73.4%
574.9K
Indaptus Therapeutics (INDP) โ€” Financials